Tore Curstedt
Overview
Explore the profile of Tore Curstedt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mikolka P, Kosutova P, Kolomaznik M, Nemcova N, Hanusrichterova J, Curstedt T, et al.
Lung
. 2024 Apr;
202(3):299-315.
PMID: 38684519
Purpose: Acute respiratory distress syndrome (ARDS) is a major cause of hypoxemic respiratory failure in adults. In ARDS extensive inflammation and leakage of fluid into the alveoli lead to dysregulation...
2.
Moya F, Curstedt T, Johansson J, Sweet D
Semin Fetal Neonatal Med
. 2023 Nov;
28(6):101503.
PMID: 38036308
No abstract available.
3.
Mikolka P, Kronqvist N, Haegerstrand-Bjorkman M, Jaudzems K, Kosutova P, Kolomaznik M, et al.
Transl Res
. 2023 Jul;
262:60-74.
PMID: 37499744
Respiratory distress syndrome (RDS) in premature infants is caused by insufficient amounts of endogenous lung surfactant and is efficiently treated with replacement therapy using animal-derived surfactant preparations. On the other...
4.
Speer C, Curstedt T, Saugstad O
Neonatology
. 2022 Dec;
120(1):1-2.
PMID: 36549281
No abstract available.
5.
Basabe-Burgos O, Landreh M, Rising A, Curstedt T, Johansson J
ACS Chem Biol
. 2021 Dec;
16(12):2864-2873.
PMID: 34878249
Treatment of respiratory distress syndrome (RDS) with surfactant replacement therapy in prematurely born infants was introduced more than 30 years ago; however, the surfactant preparations currently in clinical use are...
6.
Calkovska A, Haegerstrand-Bjorkman M, Curstedt T
Sci Rep
. 2021 Jan;
11(1):22.
PMID: 33420141
During postnatal adaptation pulmonary surfactant may be inactivated by lipopolysaccharide (LPS). We evaluated the effect of surfactant therapy in combination with antibiotic polymyxin B (PxB) in double-hit model of neonatal...
7.
Mikolka P, Curstedt T, Feinstein R, Larsson A, Grendar M, Rising A, et al.
Physiol Rep
. 2021 Jan;
9(1):e14700.
PMID: 33403805
Acute respiratory distress syndrome (ARDS) is associated with diffuse inflammation, alveolar epithelial damage, and leakage of plasma proteins into the alveolar space, which together contribute to inactivation of pulmonary surfactant...
8.
Curstedt T, Halliday H, Hallman M, Saugstad O, Speer C
Neonatology
. 2020 Jul;
117(2):204-206.
PMID: 32610329
No abstract available.
9.
Das P, Curstedt T, Agarwal B, Prahaladan V, Ramirez J, Bhandari S, et al.
Front Physiol
. 2020 Apr;
11:266.
PMID: 32327998
Background: Invasive mechanical ventilation (IMV) has become one of the mainstays of therapy in NICUs worldwide, as a result of which premature babies with extremely low birth weight have been...
10.
Stichtenoth G, Haegerstrand-Bjorkman M, Walter G, Linderholm B, Herting E, Curstedt T
Biomed Hub
. 2020 Jan;
2(2):1-9.
PMID: 31988907
Background: Ascending maternofetal bacterial infections often result in premature birth and neonatal respiratory distress. These neonates are treated with exogenous pulmonary surfactant (SF) and systemic antibiotics. Polymyxins are antimicrobiotic peptides...